Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
7.79 USD | -1.89% | -9.00% | -24.44% |
05-13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
05-08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.44% | 228M | |
+10.91% | 226B | |
+14.75% | 198B | |
+19.38% | 142B | |
+29.91% | 111B | |
+2.09% | 65.26B | |
+15.29% | 54.36B | |
+6.68% | 50.94B | |
+9.13% | 44.8B | |
+3.83% | 36.8B |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- NeuroPace : Baird Starts NeuroPace at Outperform With $26 Price Target